Insilico to present the latest developments in AI for healthcare to advance medical research
Tuesday, February 27, 2018, Baltimore, MD – Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, biomarker development and aging research, announces the lecture of its founder and CEO, Dr. Alex Zhavoronkov, at the HIMSS18 Conference, 7 March, 2018, organized by Healthcare Information and Management Systems Society (HIMSS).
Dr. Zhavoronkov's session "The convergence of healthcare's emerging tech alphabet soup with blockchain" will focus on the latest advances in Artificial Intelligence, Internet of Things, Machine Learning, and Virtual/Augmented reality making healthcare better for patients. The lecture will cover the development of robust AI-driven systems that enhance patient care and advance medical and clinical research.
"There are hundreds of projects in blockchain for healthcare and, unfortunately, many of them are using the hype cycle to fundraise instead of developing the technology. The IEEE session at the HIMSS is intended to discuss a set of standards and the possible interoperability between many systems. I am also delighted to present several models for putting the life data on blockchain and the importance of developing AI to avoid human intervention", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.
The 2018 HIMSS Conference gathers over 45,000 professionals from around the world during the five-day program dedicated to education, innovation, and collaboration to accelerate the advances in healthcare. HIMSS is a worldwide provider of thought leadership, community building, professional development, public policy, and events in the healthcare industry. Globally, the company's lead endeavors optimize health engagements and care outcomes through information and technology.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. It is the first company applied deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the recent papers published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The most recent paper published in the Oncotarget journal presented the roadmap to enhancing radioresistance for space exploration and colonization.
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD
Official Conference Website: http://www.himssconference.org
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions.
The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.
Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8